NCT05486117已完成1 期
A Phase 1 Clinical Trial to Evaluate the Pharmacokinetics of Twice-daily Applications of Delgocitinib Cream 20 mg/g for 1 Week in Adult Subjects With Moderate to Severe Chronic Hand Eczema.
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- LEO Pharma
- 入组人数
- 15
- 试验地点
- 1
- 主要终点
- Maximum observed concentration (Cmax) at Day 1 and at Day 8 (0-12 hours post-dose).
研究概览
简要总结
The purpose of the trial is to test how much delgocitinib enters the body over a given time period after application of delgocitinib cream in patients with moderate to severe hand eczema.
Delgocitinib is a cream that suppresses specific processes in the body's response to diseases like CHE, such as inflammation. Everyone in the trial will use delgocitinib cream.
The trial will last up to 7 weeks and there will be 6 visits and a phone call. There will be a screening period of up to 4 weeks, a treatment period (with blood sampling) of 11 days and a safety follow-up phone call 11 days after the last visit.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 years or above at screening.
- •Diagnosis of CHE, defined as hand eczema that has persisted for more than 3 months or returned twice or more within the last 12 months.
- •Disease severity graded as moderate to severe at screening and baseline according to IGA-CHE (i.e. an IGA-CHE score of 3 or 4).
- •Subjects who have a documented recent history of inadequate response to treatment with topical corticosteroids (TCS) (at any time within 1 year before the screening visit) or for whom TCS are documented to be otherwise medically inadvisable (e.g. due to important side effects or safety risks).
- •Subjects adherent to standard non-medicated skin care including avoidance of known and relevant irritants and allergens.
排除标准
- •Concurrent skin diseases on the hands, e.g. tinea manuum.
- •Active atopic dermatitis (AD) requiring medical treatment in regions other than the hands and feet.
- •Active psoriasis on any part of the body.
- •Hyperkeratotic hand eczema in combination with a history of psoriasis on any part of the body.
- •Clinically significant infection (e.g. impetiginised hand eczema) on the hands.
- •Systemic treatment with immunosuppressive drugs (e.g. methotrexate, cyclosporine, azathioprine), immunomodulating drugs, retinoids (e.g. alitretinoin), or corticosteroids within 28 days prior to baseline (steroid eyedrops and inhaled or intranasal steroids corresponding to up to 1 mg prednisolone for allergic conjunctivitis, asthma, or rhinitis are allowed).
- •Use of tanning beds, phototherapy (e.g. ultraviolet B [UVB], ultraviolet A1 [UVA1], psoralen ultraviolet A [PUVA]), or bleach baths on the hands within 28 days prior to baseline.
- •Cutaneously applied treatment with immunomodulators (e.g. phosphodiesterase 4 [PDE-4] inhibitors, pimecrolimus, tacrolimus) or TCS on the hands within 14 days prior to baseline.
- •Use of systemic antibiotics or cutaneously applied antibiotics on the hands within 14 days prior to baseline.
- •Cutaneously applied treatments in regions other than the hands, which could interfere with clinical trial evaluations or pose a safety concern within 7 days prior to baseline.
研究组 & 干预措施
Delgocitinib cream 20 mg/g
Experimental
Twice-daily topical application for 8 days
干预措施: Delgocitinib (Drug)
结局指标
主要结局
Maximum observed concentration (Cmax) at Day 1 and at Day 8 (0-12 hours post-dose).
时间窗: Day 1 and at Day 8 (0-12 hours post-dose)
Area under the concentration-time curve 0-12 hours post dose at Day 1 and Day 8 (AUC0-12).
时间窗: 0-12 hours post dose at Day 1 and Day 8
次要结局
- Terminal elimination half-life (t1/2) at Day 8.(Day 8.)
- Time to reach maximum observed concentration (tmax) at Day 1 and Day 8 (0-12 hours post-dose).(Day 1 and Day 8 (0-12 hours post-dose).)
- Number of treatment-emergent adverse events (AEs) from baseline to Day 22 per subject.(Baseline to Day 22)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
早期 1 期
A Trial to Evaluate the Effect of Delgocitinib on the Heart Rhythm of Healthy PeopleHealthy VolunteersHealthyNCT05050279LEO Pharma40
终止
1 期
Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I PortionMelanomaNCT00791271M.D. Anderson Cancer Center17
已完成
1 期
A Study to Assess the Pharmacokinetics, Metabolism and Excretion Routes of ASP3652 in Man, After Administration of 14C Radio Labeled ASP3652Healthy SubjectsPharmacokinetics of ASP3652NCT02046798Astellas Pharma Europe B.V.6
已完成
1 期
A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue SarcomaSoft Tissue SarcomaNeoplasms, Connective and Soft TissueNeoplasms by Histologic TypeNeoplasmsSarcomaNCT00102609Johnson & Johnson Pharmaceutical Research & Development, L.L.C.41
已完成
1 期
A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal FunctionHealthyRenal InsufficiencyNCT05469100Eli Lilly and Company37